SGMO
$0.25
Sangamo Therapeutics
($.06)
(19.66%)
SGMO
Earnings Whisper ®
N/A
1st Quarter March 2026
Consensus:  ($0.04)
Revenue:  N/A
Monday
Jun 29
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SGMO reports earnings?
Beat
Meet
Miss

Where is SGMO's stock price going from here?
Up
Flat
Down
Stock chart of SGMO
Analysts
Summary of analysts' recommendations for SGMO
Score
Grade
Pivots
Resistance
$0.31
$0.28
$0.26

$0.23

Support
$0.22
$0.19
$0.17
Tweet
Growth
Description
Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.
Peers
AmgenBiogenGilead SciencesNeurocrine BiosciencesRepligenQiagen N.V.Bio-TechneBioCryst PharmaceuticalsNovavaxStem
›